NLG 919.00
IDO pathway inhibitor / NLG919 (1402836-58-1) is a potent IDO-pathway inhibitor (Ki = 7nM; EC50 = 75nM).1 It synergizes with chemo-radiation therapy to promote T cell dependent complement deposition in a murine model of glioblastoma.2 In combination with paclitaxel in a mouse B16-F10 melanoma model, NLG919 increased the percentage of CD3+, CD8+, and CD4+ T cells and secretion of IFN-γ and interleukin-2 while decreasing the percentage of CD4+CD25+ regulatory T cells.3
Biochemicals & reagents
1402836-58-1
1) Mautino et al. (2013), NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy; Cancer Res. 73 issue 8 supplement 491 2) Li et al. (2014), The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma; J. Immunother. Cancer 2 21 3) Meng et al. (2017), Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model; Int. J. Immunopathol. Pharmacol. 30 215
-20°C
TARGET: Tryptophan -- PATHWAY: Cytokine; Amino acid metabolism; IDO/TDO pathways -- RESEARCH AREA: Immunology -- DISEASE AREA: Cancer